BioCentury
ARTICLE | Company News

FDA accepts Genzyme BLA

September 19, 2000 7:00 AM UTC

The FDA accepted for review GENZ's BLA for Fabrazyme agalsidase beta enzyme replacement therapy to treat Fabry's disease. The agency also approved GENZ's request for priority review. GENZ submitted th...